• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib.

作者信息

Li Yibin, Lin Yantang, Wu Jingxun, Ye Feng

机构信息

Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China.

出版信息

Transl Lung Cancer Res. 2020 Oct;9(5):2188-2190. doi: 10.21037/tlcr-20-847.

DOI:10.21037/tlcr-20-847
PMID:33209641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7653111/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99d9/7653111/b96386f3c7f2/tlcr-09-05-2188-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99d9/7653111/b96386f3c7f2/tlcr-09-05-2188-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/99d9/7653111/b96386f3c7f2/tlcr-09-05-2188-f1.jpg

相似文献

1
Meningeal metastasis patients with EGFR G724S who develop resistance to osimertinib benefit from the addition of afatinib.对奥希替尼产生耐药性的EGFR G724S脑膜转移患者可从阿法替尼的添加中获益。
Transl Lung Cancer Res. 2020 Oct;9(5):2188-2190. doi: 10.21037/tlcr-20-847.
2
Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report.奥希替尼联合阿法替尼治疗 EGFR T790M 突变及对厄洛替尼耐药后出现多种 HER2 改变的肺腺癌一例报告
Thorac Cancer. 2018 Dec;9(12):1774-1777. doi: 10.1111/1759-7714.12889. Epub 2018 Oct 8.
3
Synergy between next generation EGFR tyrosine kinase inhibitors and miR-34a in the inhibition of non-small cell lung cancer.下一代表皮生长因子受体酪氨酸激酶抑制剂与miR-34a在抑制非小细胞肺癌中的协同作用
Lung Cancer. 2017 Jun;108:96-102. doi: 10.1016/j.lungcan.2017.02.020. Epub 2017 Mar 1.
4
Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience.阿法替尼用于非小细胞肺癌一线治疗的临床证据和经验。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618808659. doi: 10.1177/1753466618808659.
5
Turning mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.将突变阳性非小细胞肺癌转变为慢性病：表皮生长因子受体酪氨酸激酶抑制剂的最佳序贯治疗
Ther Adv Med Oncol. 2018 Jan 22;10:1758834017753338. doi: 10.1177/1758834017753338. eCollection 2018.
6
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib.用递增剂量的阿法替尼建立并鉴定三种阿法替尼耐药的肺腺癌PC-9细胞系。
J Vis Exp. 2019 Jun 26(148). doi: 10.3791/59473.
7
The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells.Src家族激酶和粘着斑激酶的激活以及扩增、突变基因的缺失导致人肺癌细胞对阿法替尼、厄洛替尼和奥希替尼产生耐药性。
Oncotarget. 2017 Aug 7;8(41):70736-70751. doi: 10.18632/oncotarget.19982. eCollection 2017 Sep 19.
8
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis.一线治疗晚期表皮生长因子受体突变型非小细胞肺癌患者的疗效和安全性：系统评价和网络荟萃分析。
BMJ. 2019 Oct 7;367:l5460. doi: 10.1136/bmj.l5460.
9
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.阿法替尼用于奥希替尼耐药的EGFR外显子19缺失/T790M/P794L突变的非小细胞肺癌
J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.
10
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.抑制IGF1R信号传导可消除EGFR T790M突变肺癌细胞对阿法替尼（BIBW2992）的耐药性。
Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4.

引用本文的文献

1
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.奥希替尼与经治的非小细胞肺癌软脑膜转移患者预后改善相关：一项系统评价和荟萃分析。
Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15.
2
Structure-Guided Strategies of Targeted Therapies for Patients with -Mutant Non-Small Cell Lung Cancer.基于结构的 - 突变型非小细胞肺癌靶向治疗策略。
Biomolecules. 2023 Jan 20;13(2):210. doi: 10.3390/biom13020210.
3
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance.

本文引用的文献

1
Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.奥希替尼治疗进展后出现的表皮生长因子受体（EGFR）G724S突变对阿法替尼单药治疗有效。
J Thorac Oncol. 2020 Mar;15(3):e36-e37. doi: 10.1016/j.jtho.2019.09.198.
2
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.针对突变选择性 EGFR 抑制剂奥希替尼的靶标耐药可在依赖于原始 EGFR 激活突变的等位基因特异性方式下发生。
Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.
3
Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
奥希替尼耐药的表皮生长因子受体突变型非小细胞肺癌患者的治疗策略。
J Hematol Oncol. 2022 Dec 8;15(1):173. doi: 10.1186/s13045-022-01391-4.
4
L718Q/V mutation in exon 18 of EGFR mediates resistance to osimertinib: clinical features and treatment.表皮生长因子受体（EGFR）第18外显子中的L718Q/V突变介导对奥希替尼的耐药性：临床特征与治疗
Discov Oncol. 2022 Aug 9;13(1):72. doi: 10.1007/s12672-022-00537-7.
5
Successful Treatment of Afatinib Reversing Epidermal Growth Factor Receptor Exon19Deletion/G724S Mutation Resistance Guided by Protein-Drug Docking.蛋白药物对接指导下成功治疗阿法替尼逆转表皮生长因子受体外显子 19 缺失/G724S 突变耐药
Oncologist. 2021 Nov;26(11):e1903-e1908. doi: 10.1002/onco.13932. Epub 2021 Sep 12.
克服 EGFR 介导的奥希替尼耐药性：第二代 EGFR 抑制剂的独特结合特性。
Nat Commun. 2018 Nov 7;9(1):4655. doi: 10.1038/s41467-018-07078-0.
4
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer.表皮生长因子受体（EGFR）突变型肺癌中基于序贯血浆游离DNA指导的两种EGFR酪氨酸激酶抑制剂的亚克隆治疗
J Thorac Oncol. 2017 Jul;12(7):e81-e84. doi: 10.1016/j.jtho.2017.02.023. Epub 2017 Mar 7.